Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain financial results, operational updates, or strategic commentary for the period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to disclosing specific share acquisition transactions.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of American Depositary Shares (ADSs) by executives via dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, risk factors, contingencies, or discussion of unusual items. It is a regulatory disclosure of specific transactions executed on May 20, 2021, on the New York Stock Exchange.
Important Facts for Investors
- Transaction Type: All reported transactions were acquisitions of ADSs resulting from the reinvestment of dividends, not open-market purchases.
- Executives Involved:
- Dr. H. Barron (Chief Scientific Officer and President, R&D): Acquired 2,552.047 notional ADSs and 67 ADSs.
- Mr. J. Ford (SVP & General Counsel): Acquired 65.537 notional ADSs.
- Transaction Price: All shares were acquired at a price of $39.0300 per ADS.
- Transaction Date: May 20, 2021.
- Reporting Date: May 24, 2021.